Cytoflex ready to use daily qc fluorospheres reagents

Using flow cytometry, blood samples were processed with an extensive panel of human-specific monoclonal antibodies. These antibodies included anti-CD3 PerCp, anti-CD4 BV421, anti-CD8 BV605, anti-CD19 FITC, and anti-CD45 AF700, along with other antibodies targeting immune checkpoints and pertinent markers, such as anti-PD-1 APC, anti-PD-L1 PE, anti-CTLA-4 PE, anti-CD86 APC, anti-CD200 PE, and anti-CD200R APC. All of these antibodies were sourced from BioLegend (San Diego, CA, USA). For accurate gating during cytometric analysis, FMO controls were incorporated specifically for the immune checkpoints’ antibodies.
After the antibody incubation stage, red blood cells were lysed using a specific buffer from BD (Franklin Lakes, NJ, USA). This lysing solution was prepared following the manufacturer’s protocol to ensure optimal cell lysis. The post-lysis cell suspension was then washed and analyzed on the CytoFLEX LX cytometer (Beckman Coulter, Indianapolis, IN, USA). For subsequent data interpretation, Kaluza Analysis software, version 2.1, also from Beckman Coulter, was used. The CytoFLEX LX system’s consistent quality was upheld using CytoFLEX Ready to Use Daily QC Fluorospheres reagents (Beckman Coulter, Indianapolis, IN, USA). Figure 1 and Figure 2 present the results of the sample analysis.

The analysis of lymphocyte immunophenotype in peripheral blood was performed through the use of flow cytometry, a precise and accurate approach to cell analysis. A whole blood sample was collected and treated with a set of monoclonal human anti-bodies consisting of anti-CD45 AF700, anti-CD3 PerCp, anti-CD4 BV421, anti-CD8 BV605, anti-CD19 FITC, anti-CD56 BV650, and anti-CD16 BV650, as well as anti-TLR2 APC, anti-TLR3 PE, anti-TLR4 PE, anti-TLR7 PE, anti-TLR8 APC, and anti-TLR9 APC antibodies (BioLegend, San Diego, CA 92121, USA). Subsequently, a lysing buffer was utilized to remove any red blood cells, and the remaining cells were thoroughly washed and assessed through the use of a CytoFLEX LX instrument, which is a sophisticated flow cytometer (Beckman Coulter, Indianapolis, IN, USA). The resulting data were analyzed using the Kaluza Analysis program, as demonstrated in Figure 2. The CytoFLEX LX flow cytometer was subjected to daily quality control using CytoFLEX Ready to Use Daily QC Fluorospheres reagents (Beckman Coulter, Indianapolis, IN, USA).